China, Aug. 11 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A prospective, open-label, multi-cohort, phase II clinical study of vibecotuotamab combined with tislelizumab plus chemotherapy for esophageal squamous cell carcinoma'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600129512
Registration Time: 2026/08/05
Type: Interventional study
Primary Sponsor: Tianjin Medical University Cancer Institute and Hospital
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=327204
Published by HT Digital Content Services with permission from Health Daily Digest....